Anti-proliferative effect of isorhamnetin on HeLa cells through inducing G2/M cell cycle arrest

Wei,Juan; Su,Hailan; Bi,Yang; Li,Jixin; Feng,Lidan; Sheng,Wenjun

doi:10.3892/etm.2018.5892

Anti-proliferative effect of isorhamnetin on HeLa cells through inducing G2/M cell cycle arrest

Authors:
- Juan Wei
- Hailan Su
- Yang Bi
- Jixin Li
- Lidan Feng
- Wenjun Sheng
View Affiliations

Affiliations: College of Food Science and Engineering, Gansu Agricultural University, Lanzhou, Gansu 730070, P.R. China
Published online on: February 26, 2018 https://doi.org/10.3892/etm.2018.5892
Pages: 3917-3923
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a major cancer type in females, cervical cancer has been explored in depth by researchers. HeLa is a cervical cancer cell line. Isorhamnetin is an O‑methylated flavonol that is primarily extracted from sea buckthorn. In the present study, the anti-proliferative effect of isorhamnetin on HeLa cells was evaluated using a Trypan blue dye exclusion assay. Isorhamnetin inhibited the cell proliferation in a time‑ and dose‑dependent manner. Flow cytometric analysis of the cell cycle distribution revealed that isorhamnetin inhibited the cell cycle progression of HeLa by causing G2/M phase arrest and decreasing the proportion of cells in G1 phase. In addition, western blot analysis was performed to evaluate the presence of certain cell cycle‑associated proteins. It was demonstrated that isorhamnetin inhibited the protein expression of cyclin B1, cell division cycle 25C (Cdc25C) and Cdc2, but enhanced checkpoint kinase 2 (Chk2), Cdc25C and Cdc2 phosphorylation. In addition, tubulin depolymerization participated in the isorhamnetin‑induced cell cycle arrest in G2/M phase. In conclusion, the present results indicated that the anti‑proliferative action of isorhamnetin is associated with arrest of the cell cycle in G2/M phase, which is a consequence of activation of the ataxia telangiectasia mutated Chk2 pathway and disruption of microtubule function.

View Figures

View References

1	Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M and Bray F: Worldwide burden of cervical cancer in 2008. Ann Oncol. 22:2675–2686. 2011. View Article : Google Scholar : PubMed/NCBI
2	Farrand L, Oh SW, Song YS and Tsang BK: Phytochemicals: A multitargeted approach to gynecologic cancer therapy. Biomed Res Int. 2014:8901412014. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kumar D, Basu S, Parija L, Rout D, Manna S, Dandapat J and Debata PR: Curcumin and ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. Biomed Pharmacother. 81:31–37. 2016. View Article : Google Scholar : PubMed/NCBI
5	Debata PR, Castellanos MR, Fata JE, Baggett S, Rajupet S, Szerszen A, Begum S, Mata A, Murty VV, Opitz LM and Banerjee P: A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed human cervical cancer cells. Gynecol Oncol. 129:145–153. 2013. View Article : Google Scholar : PubMed/NCBI
6	Thacker PC and Karunagaran D: Curcumin and emodin down-regulate TGF-β signaling pathway in human cervical cancer cells. PLoS One. 10:e01200452015. View Article : Google Scholar : PubMed/NCBI
7	Maher DM, Bell MC, O'Donnell EA, Gupta BK, Jaggi M and Chauhan SC: Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog. 50:47–57. 2011. View Article : Google Scholar : PubMed/NCBI
8	Narayanan BA, Geoffroy O, Willingham MC, Re GG and Nixon DW: p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 136:215–221. 1999. View Article : Google Scholar : PubMed/NCBI
9	Li Y, Chi G, Shen B, Tian Y and Feng H: Isorhamnetin ameliorates LPS-induced inflammatory response through downregulation of NF-κB signaling. Inflammation. 39:1291–1301. 2016. View Article : Google Scholar : PubMed/NCBI
10	Jiang JS, Shih CM, Wang SH, Chen TT, Lin CN and Ko WC: Mechanisms of suppression of nitric oxide production by 3-O-methylquercetin in RAW 264.7 cells. J Ethnopharmacol. 103:281–287. 2006. View Article : Google Scholar : PubMed/NCBI
11	Yang JH, Kim SC, Shin BY, Jin SH, Jo MJ, Jegal KH, Kim YW, Lee JR, Ku SK, Cho IJ and Ki SH: O-Methylated flavonol isorhamnetin prevents acute inflammation through blocking of NF-κB activation. Food Chem Toxicol. 59:362–372. 2013. View Article : Google Scholar : PubMed/NCBI
12	Saud SM, Young MR, Jones-Hall YL, Ileva L, Evbuomwan MO, Wise J, Colburn NH, Kim YS and Bobe G: Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and β-catenin. Cancer Res. 73:5473–5484. 2013. View Article : Google Scholar : PubMed/NCBI
13	Yang JH, Shin BY, Han JY, Kim MG, Wi JE, Kim YW, Cho IJ, Kim SC, Shin SM and Ki SH: Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol Appl Pharmacol. 274:293–301. 2014. View Article : Google Scholar : PubMed/NCBI
14	Li Q, Ren FQ, Yang CL, Zhou LM, Liu YY, Xiao J, Zhu L and Wang ZG: Anti-proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo. Asian Pac J Cancer Prev. 16:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sobral F, Calhelha RC, Barros L, Dueñas M, Tomás A, Santos-Buelga C, Vilas-Boas M and Ferreira IC: Flavonoid composition and antitumor activity of bee bread collected in northeast Portugal. Molecules. 22(pii): E2482017. View Article : Google Scholar : PubMed/NCBI
16	Shi X, Liu D, Zhang J, Hu P, Shen W, Fan B, Ma Q and Wang X: Extraction and purification of total flavonoids from pine needles of Cedrus deodara contribute to anti-tumor in vitro. BMC Complement Altern Med. 16:2452016. View Article : Google Scholar : PubMed/NCBI
17	Strober W: Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 111:A3.B.1–3. 2015. View Article : Google Scholar
18	Lv TZ and Wang GS: Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins. Exp Ther Med. 10:323–329. 2015. View Article : Google Scholar : PubMed/NCBI
19	Burd EM: Human papillomavirus and cervical cancer. Clin Microbiol Rev. 16:1–17. 2003. View Article : Google Scholar : PubMed/NCBI
20	Miao R, Wei J, Lv M, Cai Y, Du Y, Hui X and Wang Q: Conjugation of substituted ferrocenyl to thiadiazine as apoptosis-inducing agents targeting the Bax/Bcl-2 pathway. Eur J Med Chem. 46:5000–5009. 2011. View Article : Google Scholar : PubMed/NCBI
21	Xu Y, Ching YP, Zhou Y, Chiu JF, Chen F and He QY: Multiple pathways were involved in tubeimoside-1-induced cytotoxicity of HeLa cells. J Proteomics. 75:491–501. 2011. View Article : Google Scholar : PubMed/NCBI
22	Meyn MS: Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res. 55:5991–6001. 1995.PubMed/NCBI
23	Shiloh Y: Ataxia-telangiectasia: Closer to unraveling the mystery. Eur J Hum Genet. 3:116–138. 1995. View Article : Google Scholar : PubMed/NCBI
24	Khanna KK and Jackson SP: DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet. 27:247–254. 2001. View Article : Google Scholar : PubMed/NCBI
25	O'Neill T, Giarratani L, Chen P, Iyer L, Lee CH, Bobiak M, Kanai F, Zhou BB, Chung JH and Rathbun GA: Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach. J Biol Chem. 277:16102–16115. 2002. View Article : Google Scholar : PubMed/NCBI
26	Zhao H and Piwnica-Worms H: ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol. 21:4129–4139. 2001. View Article : Google Scholar : PubMed/NCBI
27	Ahn JY, Schwarz JK, Piwnica-Worms H and Canman CE: Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60:5934–5936. 2000.PubMed/NCBI
28	Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, et al: Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol. 22:6521–6532. 2002. View Article : Google Scholar : PubMed/NCBI
29	Agarwal C, Tyagi A and Agarwal R: Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther. 5:3294–3302. 2006. View Article : Google Scholar : PubMed/NCBI
30	Pines J and Hunter T: Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature. 346:760–763. 1990. View Article : Google Scholar : PubMed/NCBI
31	Russell P and Nurse P: The mitotic inducer nim1⁺ functions in a regulatory network of protein kinase homologs controlling the initiation of mitosis. Cell. 49:569–576. 1987. View Article : Google Scholar : PubMed/NCBI
32	Kumagai A and Dunphy WG: The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell. 64:903–914. 1991. View Article : Google Scholar : PubMed/NCBI
33	Jordan MA: Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2:1–17. 2002. View Article : Google Scholar : PubMed/NCBI